Ion chromatography, A66 Ion-paired extraction, F3 Ion trap, C8 Ketamine, C32, M7, M40 Labetalol, P8 L-Ascorbyl-2-phosphate, A55 LA-ICP-MS, M4 Laser spray, A59 Laxatives, C30 LCIAPCIIMS, P9 LC-MS, A42, A43, A79, FI8, P14, P50 LC-ESI-MS, AlO, A25, A28, A51, A67, A83,M25,M27,M3l,M42 LC-MS/APCI, A34, A38 LC-MSIMS, A8, A13, A37, A39, A40, A49, A52, A76, A78, A83, F7, F2l, F26, M9, MI4, M20, P48 LC-MSIMS library, A68 Lead, BI6 Legal and judicial issues, A9, M32 Lethal dose, C26 Levetiracetam, P 15 LiquidlLiquid, FI7 Liver, B16 Liver fibrosis, C 18 LOD,A6 Lorazepam, A15, P53 Low dose, P58 LSD, A78 Marijuana, Fil Mass detector, A22 Mass spectrometry, A42, A59, A64, A69, C31 Matrix, A7l MBTFA,AI6 MDA,A4,A7 MDMA, A3, A4, All, A20, Fll, M5, M36, P43 Measurement uncertainty, F3 Meconium, M47 Medical pr<strong>of</strong>essional, F26 Melanin, M3, M14 Mellanby, B17 Meprobamate, C6 Mercury analysis, C 19 Mercury poisoning, C 19 Metabolic acidosis, C25 Metabolism, C9, C33 Metabolites, A29, C3l Metalloids, A22 Metals analysis, C4 Metaxalone, P7 Methadone, C22, F17, Ml, P19, P20, P40,P60,P6l Methamphetamine, A4, B14, CIl, C28, M4l,M47,P39,P4l Methamphetamine chronic toxicity, P36 Methcathinone, C7 Method development, A42, A 79 Method Validation, A57, FI5, M5 5-Methoxy-alpha-methyltryptamine, P2I 5-Methoxy-N,N-diisopropyltryptamine, C9 Methylation, P39 Methylhippuric acid, A5I Microdiffusion method, A66 Microvascular Endothelium, M43 Microwave-assisted Extraction, M 19 Mirtazapine, P 13 6-mono-acetyl Morphine, FlO Monoliths, A 7 Morphine, F8, F13, F16, P24, P25 Multicenter evaluation, A48 Multiple Analyte Enzyme Immunoassay, FI Multi target screening, A68 Multisite sampling, MI8 Nail analysis, M30 Nails, M26 Naloxone, A83 Napoleon, C34, P45 Narcotics, C27 NAS, C22 Neonate, P54 Nerve gas, C8 Nicotine, C22, M22 Nicotine metabolites, M22 Nitrite, F2 N,N-dimethylamphetamine, F18 NNSL, F14 Page 405
Non-controlled psychotropic substances, A61 Non-negative, Fl4 Non-regulated testing, F20 11-nor-delta-9-carboxytetrahydrocannabinol, F5 Norephedrine, P42 Norketamine, C32 Nornaloxone, A83 Noscapine metabolites, F9 On-Site testing, F6, M33, M36 Opiates, A44, A64, C2, F7, M12, P30 Opioids, A16, BI4 Oral administration <strong>of</strong>THC, B2, M17, M23 Oral Cannabinoids, M38 Oral fluid, MI5, M22, M24, M27, M31, M33,M34,M36,M37,M48,M49,M50 OraSure, M17 Organophosphorous pesticides, A54 Outcomes, C22 Overdose, C6, PI, P8, P51, P55 Oxcarbazepine, P9 Oxycodone,A32,CI3,F24,P20,P26 Oxymorphone, CI3 P450, C33 Paclitaxel, A 79 Paint thinner abuser, A51 Papaverine metabolites, F9 Paramethoxyamphetamine, P41 Pediatric, P52 Perfonnance toxicology, B 11 Pennethrin, P34 Phannaceutical testing, C27 Phannacogenomics, CI7, P60, P61 Pharmacokinetics, A84 Phenazepam, A80 Phenethylamines, A61, A67 Piperazine, A 7 4 Plasma, A38, M23, M24 PMA,A26 Poisoning, C24, C26, P22 Portugal, B 12 Positive chemical ionization, A 15 Positive rates, F26 Postmortem, PII, P13, PI5, PI8, P24, P26,P31,P34,P37,P38,P47,P5I,P56, P58,P62 Postmortem blood concentrations, P33, P59 Postmortem diffusion, P4 Postmortem ethanol, P50 Postmortem fluids and tissues, PI9 Postmortem redistribution, P3, P6, P 17 Postmortem specimens, M 18, P2, P5 Postmortem toxicology, P23, P46, P52, P53,P55 Post-rotational nystagmus, B6 Posturography, B5 Pregnancy, M46 Prenatal, C22 Pr<strong>of</strong>iling, A26 Pr<strong>of</strong>iling MDMA, AI2 Propylene glycol, C25 Protease, F5 Psilocin, A34, FII Psychomotor performance, B 10 Puffer fish, C 16 Putrefaction, P4 Pyrolysis products, A29 Pyrosequencing, P60 Quantitation, A45, A49, A71, A80 Quetiapine, PII, P55, P56 Rat, C18, P3 Redistribution, P43 Residue cytotoxicity ACTP, C12 Retention time locking, A 70 rhuEPO, A65 RIA, A57 Roadside survey, B 15 Saliva, All, M21, M24, M42 Salivette, M17 SAMHSA, F14 Sampling, A20 San Francisco, P28 Scatchard Analysis, M3 Science and law, A9 Screening, A28, A40, A62, F23 Sebum, MI9 Segmental Hair Analysis, M6, M32 Self-injurious behavior, B14 Page 406
- Page 1 and 2: KeY'Nord Index Abdomen pain, C II
- Page 3: Environmental toxicology, C4 Enzyme
- Page 7 and 8: Presenting Author Index . · A'
- Page 9 and 10: Parker Dawn R PS6 Paterson Sue F9 I
- Page 11 and 12: At DETERMINATION OF PHENETHYLAMINE
- Page 13 and 14: A3 COMPARISON OF THE SENSITIVITY A
- Page 15 and 16: AS SURVEY ON FORENSIC TOXICOLOGICA
- Page 17 and 18: A7 QUANTITATIVE DETERMINATION OF A
- Page 19 and 20: A9 . RESOURCE GUIDE FOR USERS OF S
- Page 21 and 22: All DIRECT ANALYSIS OF MDMA AND MET
- Page 23 and 24: A13 SCREENING FOR ACE INHIBITORS A
- Page 25 and 26: A15 ANALYSIS FOR LORAZEPAM IN BLOO
- Page 27 and 28: A17 HIGH.PERFORMANCE LIQUID CHROMA
- Page 29 and 30: A19 PERFORMANCE OF ASSAYS FOR THER
- Page 31 and 32: A21 ALCOHOL DETERMINATION BY HEAD
- Page 33 and 34: A23 THE EXTRACTION AND ANALYSIS OF
- Page 35 and 36: A25 A RAPID METHOD FOR MEASURING AN
- Page 37 and 38: A27 EFFECT OF SODIUM CHLORIDE ON H
- Page 39 and 40: A29 SIMULTANEOUS DETERMINATION OF
- Page 41 and 42: A31 ANALYSIS OF TETRAHYDROCANNABIN
- Page 43 and 44: A33 EVALUATION OF BUPRENORPHINE CE
- Page 45 and 46: A35 ETHYLGLUCRONIDE ANALYSIS IN UR
- Page 47 and 48: ..~. A37 HIGH THROUGHPUT SCREENING
- Page 49 and 50: A39 RAPID DETERMINA nON OF CHLORAM
- Page 51 and 52: A41 DETERMINATION OF STRYCHNINE IN
- Page 53 and 54: A43 SIMULTANEOUS DETERMINATION OF
- Page 55 and 56:
A45 FAST QUANTIFICATION OF ETHANOL
- Page 57 and 58:
A47 STABILITY OF PLASMA ACETALDEHY
- Page 59 and 60:
A49 AN LC-MSIMS METHOD FOR THE QUA
- Page 61 and 62:
AS1 SIMULTANEOUS ANALYSIS OF HIPPU
- Page 63 and 64:
AS3 DETERMINATION OF ETHYL GLUCURO
- Page 65 and 66:
ASS EFFECTS OF ASCORBATE DERJV A T
- Page 67 and 68:
A57 ELISA FOR THE SCREENING OF OPI
- Page 69 and 70:
A59 DETERMINATION OF ACONITINE ALK
- Page 71 and 72:
A61 SIMULTANEOUS ANALYSIS FOR PSYC
- Page 73 and 74:
A63 SOLID-PHASE MICROEXTRACTION BAS
- Page 75 and 76:
A65 A STUDY OF CROSS-REACTIVITY OF
- Page 77 and 78:
A67 A GENERAL SCREENING AND CONFIR
- Page 79 and 80:
A69 FORENSIC DRUG ANALYSIS WITHOUT
- Page 81 and 82:
A71 USE OF STANDARD ADDITION/STAND
- Page 83 and 84:
A73 PREVALENCE OF GHB IN SUSPECTED
- Page 85 and 86:
A7S IDENTIFICATION AND ISOLATION O
- Page 87 and 88:
A77 DETERMINING THE USE OF N1-ETHY
- Page 89 and 90:
A79 LC-MSIMS METHOD DEVELOPMENT FO
- Page 91 and 92:
A81 PHENMETRAZINE OR EPHEDRINE FOO
- Page 93 and 94:
A83 DETERMINA TION OF NALOXONE AND
- Page 95 and 96:
Scientific Session Abstracts: Beh
- Page 97 and 98:
B2 PROSPECTIVE STUDY ABOUT THE EFF
- Page 99 and 100:
B4 REASONS FOR OVERESTIMATION OF T
- Page 101 and 102:
B6 EVALUATION OF THE POST-ROTATION
- Page 103 and 104:
B8 TOXICOLOGICAL FINDINGS IN CASES
- Page 105 and 106:
BIO LOW BLOOD ALCOHOL LEVELS, ATTEN
- Page 107 and 108:
B12 DRUGS OF ABUSE IN PORTUGAL; A
- Page 109 and 110:
B14 EFFECTS OF OPIOIDS ON METHAMPH
- Page 111 and 112:
B16 AMELIORATION OF LEAD TOXICITY
- Page 113 and 114:
·Scientific Session Abstracts: C
- Page 115 and 116:
C2 PARADOXICAL RESULTS FROM SCREEN
- Page 117 and 118:
C3 ALUMINUM TESTING IN TRACE-METAL
- Page 119 and 120:
C5 DETECTION OF NITRAZEPAM USING I
- Page 121 and 122:
C7 METHCATHINONE: A NEW POSTINDUST
- Page 123 and 124:
C9 A PROPOSED SCHEME FOR FOXY META
- Page 125 and 126:
ell ABDOMINAL COMPLICATION OF INHAL
- Page 127 and 128:
C13 A HOMOGENEOUS ENZYME IMMUNOASS
- Page 129 and 130:
CIS RAPID DETERMINATION OF CAUSATI
- Page 131 and 132:
C17 CHANGES OF GENE EXPRESSION BEF
- Page 133 and 134:
C19 A CASE OF SURREPTITIOUS NON-FA
- Page 135 and 136:
e21 RAPID, SIMPLE AND V ALIDA TED G
- Page 137 and 138:
C23 BIOMONITORING OF EXPOSURE TO C
- Page 139 and 140:
C25 PROPYLENE GLYCOL IN EXTREMELY
- Page 141 and 142:
C27 PHARMACEUTICAL IDENTIFICATION
- Page 143 and 144:
C29 AN EVENT ASSOCIATED WITH FATAL
- Page 145 and 146:
C31 DETECTION OF NEW MINOR METABOL
- Page 147 and 148:
C33 NOVEL ASPECTS OF IN VITRO META
- Page 149 and 150:
Scientific Session Abstracts: . F
- Page 151 and 152:
F2 URINE ADUL TERA TION TRENDS FROM
- Page 153 and 154:
F5 PAPAIN, A NOVEL URINE ADULTERAN
- Page 155 and 156:
F6 A COMPARATIVE EVALUATION OF THE
- Page 157 and 158:
F8 UNUSUAL DRUG TEST RESULTS FROM
- Page 159 and 160:
FlO EFFECTIVENESS OF FREE AND TOTAL
- Page 161 and 162:
F12 TITLE: AMPHETAMINE CONCENTRATI
- Page 163 and 164:
F14 AUTOMATED APPROACH TO NON-NEGA
- Page 165 and 166:
F16 URINARY EXCRETION OF MORPHINE
- Page 167 and 168:
FI8 A RAPID LCIMS METHOD FOR THE D
- Page 169 and 170:
F20 CONFIRMATION RATES OF INITIAL
- Page 171 and 172:
F22 USE OF COMPOUNDS ALTERING VIGI
- Page 173 and 174:
F23 SCREENING OF BUPRENORPHINE IN
- Page 175 and 176:
F25 IDENTIFICATION OF CHLORINATED
- Page 177 and 178:
F27 LINEAR RELATIONSHIPS OF 6.-9-T
- Page 179 and 180:
Ml COMPARISON STUDY OF SPE AND HS-S
- Page 181 and 182:
M3 AMPHETAMINE BINDING TO SYNTHETI
- Page 183 and 184:
M5 METHOD VALIDATION AND DETERMINA
- Page 185 and 186:
M7 EVALUATION OF KETAMINE ABUSE US
- Page 187 and 188:
M9 SCREENING OF BENZODIAZEPINES AN
- Page 189 and 190:
Mll DIAGNOSIS OF CHRONIC ALCOHOL CO
- Page 191 and 192:
M13 EVIDENCE OF ADDICTION BY ANAES
- Page 193 and 194:
M15 DRUG DETECTION IN ORAL FLUID:
- Page 195 and 196:
M17 CANNABINOID ANALYSIS OF ORAL F
- Page 197 and 198:
M19 METHOD DEVELOPMENT OF MICROWAV
- Page 199 and 200:
M21 IMPROVED GCMS ANALYSIS OF THC
- Page 201 and 202:
M23 ~9-TETRAHYDROCANNABINOL (THC),
- Page 203 and 204:
M25 ,--- LIQUID CHROMATOGRAPHY -
- Page 205 and 206:
M27 DETERMINA TION OF THC IN ORAL
- Page 207 and 208:
M29 CODEINE AND METABOLITE DISPOSI
- Page 209 and 210:
M31 DETERMINATION OF A'.TETRAHYDRO
- Page 211 and 212:
M33 ENHANCED SENSITIVITY FOR DRUGS
- Page 213 and 214:
M35 DRUG DETECTION IN HAIR: ASSESS
- Page 215 and 216:
M37 ALCOHOL TESTING BY AN ONSITE O
- Page 217 and 218:
M39 QUANTITATIVE ANALYSIS OF DEXTR
- Page 219 and 220:
M41 GAS CHROMATOGRAPHY:'HIGH-RESOLU
- Page 221 and 222:
M43 COCAETHYLENE: A POTENTIALLY LE
- Page 223 and 224:
M45 DETECTION OF COTININE IN EXHAL
- Page 225 and 226:
M47 METHAMPHETAMINE AND AMPHETAMIN
- Page 227 and 228:
M49 DISPOSITION OF NJ-TETRAHYDROCAN
- Page 229 and 230:
MSl DISPOSITION OF COCAINE AND META
- Page 231 and 232:
PI NEW GENERATIONS OF ANTIDEPRESAN
- Page 233 and 234:
P3 POSTMORTEM REDISTRIBUTION OF TH
- Page 235 and 236:
PS POSTMORTEM DETERMINATION OF SIL
- Page 237 and 238:
P7 A COMBINED DRUG INTOXICATION IN
- Page 239 and 240:
P9 DETERMINATION OF OXCARBAZEPINE
- Page 241 and 242:
PH DISTRIBUTION OF QUETIAPINE IN N
- Page 243 and 244:
P13 MIRTAZAPINE-RELATED DEATHS R A
- Page 245 and 246:
PIS LEVELS OF LEVETIRACETAM IN POS
- Page 247 and 248:
P17 POSTMORTEM DISTRIBUTION OF TRA
- Page 249 and 250:
P19 EVALUA TION OF DEBATED QUESTIO
- Page 251 and 252:
P21 "STUDENT ON ALPHA-METHYLTRYPTA
- Page 253 and 254:
P23 CASE REPORT: THE USE OF AMITRI
- Page 255 and 256:
P25 ECSTACY MANUFACTURE: A CASE FO
- Page 257 and 258:
P27 ANALYSIS OF POSTMORTEM BONEIBO
- Page 259 and 260:
P29 THE ROLE OF COCAINE IN HEROIN
- Page 261 and 262:
P31 TRENDS IN THE DETECTION OF DRU
- Page 263 and 264:
P33 POSTMORTEM CASES RELATED TO COC
- Page 265 and 266:
P35 CARBON MONOXIDE AND ETHANOL IN
- Page 267 and 268:
P37 QUANTITA TIVE APPROACH TO DRUG
- Page 269 and 270:
P39 FORMALIN-INDUCED METHAMPHETAMI
- Page 271 and 272:
P41 SURVEY OF ABUSED DRUGS IN PERI
- Page 273 and 274:
P43 "ECSTASY" IN THE A.M. AND P.M.
- Page 275 and 276:
P45 ARSENIC IN NAPOLEON'S HAIR: IS
- Page 277 and 278:
P47 INTERPRETATION OF POSTMORTEM A
- Page 279 and 280:
P49 ALFENTANIL FATAL INJECTION: A
- Page 281 and 282:
PSt UNUSUAL TRAMADOL CONCENTRATIONS
- Page 283 and 284:
P53 LORAZEPAM AND DEATH INVESTIGAT
- Page 285 and 286:
P55 QUETIAPINE CONCENTRATIONS IN I
- Page 287 and 288:
PS7 CAFFEINE INTOXICA nON: MORE TH
- Page 289 and 290:
P59 INTERPRETING ANTIHISTAMINE LEV
- Page 291 and 292:
P61 A MULTI-CENTER STUDY OF PHARMA
- Page 293 and 294:
P63 GHB CONCENTRATIONS IN A V ARlE
- Page 295:
P65 POSTMORTEM BLOOD ALCOHOL RELIAB